Vantage Biosciences is an ALSA Ventures company at the forefront of targeting the root cause of vision loss associated with diabetes.
Investors 1
| Date | Name | Website |
| 21.07.2023 | ALSA Ventu... | alsaventur... |
Mentions in press and media 2
| Date | Title | Description |
| 04.08.2026 | Vantage Biosciences Completes Enrollment in Phase 2 SeeClear Study of Oral Oruvestat in Non-Proliferative Diabetic Retinopathy | LONDON, 4 August 2026 - Vantage Biosciences today announced that it has completed patient enrollment in the Phase 2 SeeClear study (VX01-DR-201) of oruvestat (VX-01), an investigational, orally administered inhibitor of amine oxidase copper... |
| 19.07.2023 | ALSA Ventures launches Vantage Biosciences to treat Diabetic Eye Disease | · Diabetic eye diseases are the leading cause of blindness in the working age population |